Key facts
- It has raised $940K; the latest was Seed Round ($940K) in Jan 2026.
- Notable investors include SFC Capital, Techstart Ventures, Clarendon Fund Managers, InterTradeIreland, The University of Strathclyde.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Biomarx
- ·The full record, as it builds
Funding rounds
No funding rounds for Biomarx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biomarx
Developer of a liquid biopsy-based molecular diagnostics platform designed to deliver rapid and accessible genomic testing at the point of care. The company offers an automated sample-to-result system using single-use cartridges and biosensing technologies, enabling clinicians and healthcare providers to perform reliable molecular diagnostics closer to patients and reduce dependence on centralized laboratories.
- Sector
- Healthcare
- HQ
- Belfast, United Kingdom
- Founded
- 2025
- Employees
- 1
- Website
- biomarx.co.uk/
- Ownership
- Privately Held (backing)
Biomarx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biomarx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biomarx in its N-PORT filings yet. We sweep new filings monthly.